NKp30/NCR3 Antibody (MM0490-9D31) [CoraFluor™ 1]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-11819CL1
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
CyTOF-ready, Flow Cytometry
Label
CoraFluor 1
Antibody Source
Monoclonal Mouse IgG2 Clone # MM0490-9D31
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for NKp30/NCR3 Antibody (MM0490-9D31) [CoraFluor™ 1]
Immunogen
Human recombinant NKp30/NCR3
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2
Description
CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(IM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
Applications for NKp30/NCR3 Antibody (MM0490-9D31) [CoraFluor™ 1]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark. Do not freeze.
Background: NKp30/NCR3
Given its role in NK cell-mediated killing and activation, NKp30 is a potential target for cancer immunotherapies (6). For instance, Bi-specific T cell engagers (BiTE) is one immunotherapy approach targeting the NKp30/B7-H6 interaction where B7-H6-specific BiTE elicits an attack on tumor cells through interferon gamma (IFNgamma) production and T cell cytotoxicity (1). Another potential approach is NKp30-derived chimeric antigen receptors (CARs) where CAR-T cells that express chimeric NKp30 receptors can efficiently attack B7-H6 tumor cells (1,6).
References
1. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The natural cytotoxicity receptors in health and disease. Frontiers in Immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909
2. Uniprot (O14931)
3. Luczo, J. M., Ronzulli, S. L., & Tompkins, S. M. (2021). Influenza A virus hemagglutinin and other pathogen glycoprotein interactions with NK cell natural cytotoxicity receptors NKp46, NKp44, and NKp30. Viruses, 13(2), 156. https://doi.org/10.3390/v13020156
4. Pazina, T., Shemesh, A., Brusilovsky, M., Porgador, A., & Campbell, K. S. (2017). Regulation of the Functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression. Frontiers in Immunology, 8, 369.
5. Kaifu, T., Escaliere, B., Gastinel, L. N., Vivier, E., & Baratin, M. (2011). B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and Molecular Life Sciences : CMLS, 68(21), 3531-3539. https://doi.org/10.1007/s00018-011-0802-7
6. Pinheiro, P. F., Justino, G. C., & Marques, M. M. (2020). NKp30 - A prospective target for new cancer immunotherapy strategies. British Journal of Pharmacology, 177(20), 4563-4580. https://doi.org/10.1111/bph.15222
Alternate Names
CD337, NCR3
Gene Symbol
NCR3
Additional NKp30/NCR3 Products
Product Documents for NKp30/NCR3 Antibody (MM0490-9D31) [CoraFluor™ 1]
Product Specific Notices for NKp30/NCR3 Antibody (MM0490-9D31) [CoraFluor™ 1]
CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...